Cardioselective beta-blockers for reversible airway disease

Salpeter, Shelley R.; Ormiston, Thomas M.; Salpeter, E. E.; Wood‐Baker, Richard

doi:10.1002/14651858.cd002992

Cited by 88 publications

(82 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…CASTIGLIA et al [19] extensively reviewed this issue and raised some speculative and interesting observations. Additionally, a meta-analysis investigated the effect of cardioselective beta-blockers on the respiratory function of patients with "reactive" airway disease, defined by the authors as asthma or COPD with a reversible obstructive component [20]. This definition probably includes those patients who would nowadays be defined as having ACOS.…”

Section: Beta-blockers In Copd and Cardiovascular Comorbiditiesmentioning

confidence: 99%

“…In particular, the findings of this meta-analysis underscored that the use of β 1 -blockers is safe with regard to pulmonary function and respiratory symptoms, and is not associated with increased use of inhaled β 2 -agonists. Moreover, among β 1 -selective beta-blockers, those without intrinsic sympathetic activity cause a lower forced expiratory volume in 1 s (FEV1) reduction than the other categories of beta-blocker, which can be noted after the first administration [20]. Furthermore, they appear to cause an upregulation and sensitisation of β 2 -receptors, resulting in an increased response to exogenous β 2 -agonists.…”

Section: Beta-blockers In Copd and Cardiovascular Comorbiditiesmentioning

confidence: 99%

See 1 more Smart Citation

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities

Corrao

Brunori²,

Lupo³

et al. 2017

Eur Respir Rev

View full text Add to dashboard Cite

Chronic obstructive pulmonary disease (COPD) is the most common chronic respiratory disease and its prevalence is increasing worldwide, in both industrialised and developing countries. Its prevalence is ∼5% in the general population and it is the fourth leading cause of death worldwide. COPD is strongly associated with cardiovascular diseases; in fact, ∼64% of people suffering from COPD are treated for a concomitant cardiovascular disease and approximately one in three COPD patients die as a consequence of cardiovascular diseases.Inhaled bronchodilators might have adverse cardiovascular effects, including ischaemic events and arrhythmias, and beta-blockers might adversely influence the respiratory symptoms and the response to bronchodilators. For these reasons, it is important to know the safety profiles and the possible interactions between these two classes of drug, in order to prescribe them with greater awareness.In this article, we review the literature about the epidemiology of COPD, its association with cardiovascular diseases, and the safety of concurrent use of inhaled bronchodilators and beta-blockers, as a tool for improving the approach to complex therapies in clinical practice.

show abstract

Section: Beta-blockers In Copd and Cardiovascular Comorbiditiesmentioning

confidence: 99%

Section: Beta-blockers In Copd and Cardiovascular Comorbiditiesmentioning

confidence: 99%

Effectiveness and safety of concurrent beta-blockers and inhaled bronchodilators in COPD with cardiovascular comorbidities

Corrao

Brunori²,

Lupo³

et al. 2017

Eur Respir Rev

View full text Add to dashboard Cite

show abstract

“…In patients with asthma and chronic obstructive pulmonary disease (COPD) who have a component of reversible airflow limitation, acute bronchospasm with beta-blockers is more likely. However, in one study, patients with COPD and coronary artery disease benefited from β-blockers; thus, β-blockers use in patients with COPD is not avoided (13,14). Up to 20% of asthmatic patients cannot tolerate aspirin and other NSAIDS (15).…”

Section: Bronchospasmmentioning

confidence: 99%

Drug induced pulmonary parenchymal disease

Prasad

Gupta

Singh

et al. 2014

DD&T

View full text Add to dashboard Cite

“…"The reality of everyday practice is still very low doses and low frequency of b-blocker prescription." Chronic obstructive pulmonary disease is still very often a reason for nonprescription of b-blockers to patients who have an indication, irrespective of existing evidence of high-tolerance of especially cardio-selective b-blockers [5][6][7]. Also in the SHIFT study, concurrent chronic obstructive pulmonary disease was the main reason (37%) for not giving b-blockers to 344 patients in the trial.…”

mentioning

confidence: 99%